Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya

Article English OPEN
Iriemenam, Nnaemeka C ; Shah, Monica ; Gatei, Wangeci ; van Eijk, Anna ; Ayisi, John ; Kariuki, Simon ; Vanden Eng, Jodi ; Owino, Simon O ; Lal, Ashima A ; Omosun, Yusuf O ; Otieno, Kephas ; Desai, Meghna ; terKuile, Feiko ; Nahlen, Bernard ; Moore, Julie ; Hamel, Mary J ; Ouma, Peter ; Slutsker, Laurence ; Shi, Ya Ping (2012)
  • Publisher: BioMed Central
  • Journal: Malaria Journal (vol: 11, pp: 134-134)
  • Related identifiers: doi: 10.1186/1475-2875-11-134, pmc: PMC3390272
  • Subject: qx_135 | Infectious Diseases | qv_256 | dhps | Malaria in pregnancy | wa_395 | Research | wa_310 | Kenya | wq_256 | SP resistance | Parasitology | dhfr
    mesheuropmc: parasitic diseases

Background\ud Resistance to sulphadoxine-pyrimethamine (SP) in Plasmodium falciparum parasites is associated with mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes and has spread worldwide. SP remains the recommended drug for intermittent preventive treatment for malaria in pregnancy (IPTp) and information on population prevalence of the SP resistance molecular markers in pregnant women is limited. \ud \ud Methods\ud Temporal trends of SP resistance molecular markers were investigated in 489 parasite samples collected from pregnant women at delivery from three different observational studies between 1996 and 2009 in Kenya, where SP was adopted for both IPTp and case treatment policies in 1998. Using real-time polymerase chain reaction, pyrosequencing and direct sequencing, 10 single-nucleotide polymorphisms (SNPs) of SP resistance molecular markers were assayed. \ud \ud Results\ud The prevalence of quintuple mutant (dhfr N51I/C59R/S108N and dhps A437G/K540E combined genotype) increased from 7 % in the first study (1996–2000) to 88 % in the third study (2008–2009). When further stratified by sample collection year and adoption of IPTp policy, the prevalence of the quintuple mutant increased from 2.4 % in 1998 to 44.4 % three years after IPTp policy adoption, seemingly in parallel with the increase in percentage of SP use in pregnancy. However, in the 1996–2000 study, more mutations in the combined dhfr/dhps genotype were associated with SP use during pregnancy only in univariable analysis and no associations were detected in the 2002–2008 and 2008–2009 studies. In addition, in the 2008–2009 study, 5.3 % of the parasite samples carried the dhps triple mutant (A437G/K540E/A581G). There were no differences in the prevalence of SP mutant genotypes between the parasite samples from HIV + and HIV- women over time and between paired peripheral and placental samples. \ud \ud Conclusions\ud There was a significant increase in dhfr/dhps quintuple mutant and the emergence of new genotype containing dhps 581 in the parasites from pregnant women in western Kenya over 13 years. IPTp adoption and SP use in pregnancy only played a minor role in the increased drug-resistant parasites in the pregnant women over time. Most likely, other major factors, such as the high prevalence of resistant parasites selected by the use of SP for case management in large non-pregnant population, might have contributed to the temporally increased prevalence of SP resistant parasites in pregnant women. Further investigations are needed to determine the linkage between SP drug resistance markers and efficacy of IPTp-SP.
  • References (65)
    65 references, page 1 of 7

    1. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO: Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 2010, 7:e1000221.

    2. WHO: Lives at risk: malaria in pregnancy.: ; 2003. [http://www.who.int/ features/2003/04b/en/] (Accessed 14 December 2010).

    3. WHO: World Malaria Report 2008. Geneva, Switzerland: WHO Press; 2008.

    4. WHO: A strategic framework for malaria prevention and control during pregnancy in the Africa region. Brazzaville, Congo: WHO Regional Office for Africa; 2004. AFR/MAL/04/01.

    5. Maiga OM, Kayentao K, Traore BT, Djimde A, Traore B, Traore M, Ongoiba A, Doumtabe D, Doumbo S, Traore MS, Dara A, Guindo O, Karim DM, Coulibaly S, Bougoudogo F, Ter Kuile FO, Danis M, Doumbo OK: Superiority of 3 over 2 doses of intermittent preventive treatment with sulphadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trial. Clin Infect Dis 2011, 53:215-223.

    6. Goodman CA, Coleman PG, Mills AJ: The cost-effectiveness of antenatal malaria prevention in sub-Saharan Africa. AmJTrop Med Hyg 2001, 64:45-56.

    7. Sicuri E, Bardaji A, Nhampossa T, Maixenchs M, Nhacolo A, Nhalungo D, Alonso PL, Menendez C: Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS One 2010, 5:e13407.

    8. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K: Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999, 353:632-636.

    9. Asa OO, Onayade AA, Fatusi AO, Ijadunola KT, Abiona TC: Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women. Matern Child Health J 2008, 12:692-698.

    10. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW: Efficacy of sulphadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. AmJTrop Med Hyg 1998, 59:813-822.

  • Related Research Results (4)
  • Metrics
    No metrics available
Share - Bookmark